TY  -  JOUR
AU  -  Zavaleta Monestel, Esteban
AU  -  García-Montero, Jonathan
AU  -  Martínez Vargas, Ernesto
AU  -  Rojas Chinchill, Carolina
AU  -  Gabuardi Bautista, David
AU  -  Langella, Roberto
AU  -  Zovi, Andrea
T1  -  Pharmacovigilance activity in a Latin American Hospital: evaluating clinical pharmacists’ contributions to adverse event reporting
PY  -  2025
Y1  -  2025-01-01
DO  -  10.1721/4489.44896
JO  -  Giornale Italiano di Farmacia Clinica
JA  -  GIFAC
VL  -  39
IS  -  1
SP  -  46
EP  -  50
PB  -  Il Pensiero Scientifico Editore
SN  -  1120-3749
Y2  -  2026/03/15
UR  -  http://dx.doi.org/10.1721/4489.44896
N2  -  Summary. Introduction. Adverse events in healthcare pose a significant threat to patients, and underreporting, particularly in private hospitals, exacerbates the issue. Clinical pharmacists play a crucial role in detecting and reporting these adverse events. This analysis aims to characterize the adverse events reported in a private hospital in Costa Rica, providing a detailed description of their frequency, severity, pharmacological groups involved, and management strategies. Materials and methods. A retrospective and documentary analysis was carried out based on the reports of adverse events recorded at the Clínica Bíblica Hospital between January 2021 and December 2023. A total of 497 adverse event reports from the hospital’s internal pharmacovigilance system were included. The data were analyzed using descriptive statistics, classifying the events according to their severity, pharmacological group and type of intervention performed. Results. Of the total number of reports analyzed, 95.37% were classified as non-preventable and 4.63% as preventable. Most adverse events were mild (83.70%), while 2.62% were classified as serious. Vaccines accounted for the highest proportion of reported adverse events (45.27%), followed by anti-infectives (11.07%) and systemic steroids (10.66%). Regarding management, 47.98% of patients tolerated the event without intervention, while in 26.61% of cases a medication was administrated to mitigate adverse effects. Conclusions. The findings show the importance of strengthening pharmacovigilance systems in private hospitals, given that adverse events are still underreported. It is necessary to promote a culture of notification among health professionals and promote the integration of digital tools that facilitate the reporting and analysis of these events, thus contributing to safer and more efficient care.
ER  -